Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Peter Schmid, MD, PhD, Barts Cancer Center

Videos

Addition of Pembrolizumab to Neoadjuvant Chemotherapy Plus Adjuvant Pembrolizumab Improved EFS Among Patients with Early-Stage Triple-Negative Breast Cancer

12/08/2023

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.

Peter Schmid, MD, PhD, presents...

12/08/2023

Oncology

Michail Ignatiadis, MD, PhD, Jules Bordet Institute

Videos

No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer

12/07/2023

Michail Ignatiadis , MD, PhD;

Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.

Michail Ignatiadis, MD, PhD,...

12/07/2023

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer

12/07/2023

Cynthia Ma , MD;

Neelima Vidula , MD;

Seth Wander , MD;

Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 2 of...

12/07/2023

Oncology

Sara Hurvitz, MD, Fred Hutchinson Cancer Center

Videos

Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer

12/06/2023

Sara Hurvitz , MD;

Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.

Sara Hurvitz, MD, shares results...

12/06/2023

Oncology

Videos

Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer

11/30/2023

Cynthia Ma , MD;

Neelima Vidula , MD;

Seth Wander , MD;

Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...

Cynthia Ma, MD, leads part 1 of...

11/30/2023

Oncology

Sherene Loi, MBBS, PhD, Peter MacCallum Cancer Center

Videos

Adding Nivolumab to Neoadjuvant Chemotherapy Improved Response Rate Among Patients With High Risk, ER Positive, HER2 Negative Breast Cancer

10/21/2023

Sherene Loi , MBBS, PhD;

At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.

At the 2023 ESMO Annual...

10/21/2023

Oncology

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute

Videos

Sacituzumab Govetican Improves Survival Outcomes For Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/08/2023

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

Sara Tolaney shares the final...

06/08/2023

Oncology

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

HER3-DXd for Metastatic Breast Cancer Across Subtypes

06/05/2023

At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.

At the 2023 ASCO Annual Meeting,...

06/05/2023

Oncology

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA

Videos

Genomic Differences Among HER2-Low, HER2-Zero, and HER2-Positive Breast Cancer

04/28/2023

Paolo Tarantino, MD, discusses advancements in genomic study and treatment efficacy for HER2-Low, HER2-Zero, and HER2-Positive breast cancers.

Paolo Tarantino, MD, discusses...

04/28/2023

Oncology

Mylin Torres, MD, Winship Cancer Institute

Videos

Five-Fraction Radiation Regimens for Early-Stage Breast Cancer

03/20/2023

At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.

At the 2023 ACRO Radiation...

03/20/2023

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology